Acute promyelocytic leukemia (APL) has been recognized as a discrete subset of hematopoietic malignancies constituting approximately 10% of acute myeloid leukemia cases. The hallmark reciprocal chromosomal translocation t(15;17) involving fusion between the retinoic acid receptor (RARα) gene and promyelocytic leukemia (PML) gene is a characteristic feature in APL which consequently results in the emergence of PML-RARα chimeric gene. This gene has been substantiated to be responsible for cellular transformation and is a prime target of all-trans-retinoic acid (ATRA) as well as arsenic-trioxide (ATO) therapy. Since this initial discovery, about 10 diverse translocation partner genes of RARα have been reported that result in variant APL forms strongly suggesting that disruption of RARα underlies its pathogenesis. The nature of the fusion partner has a significant bearing upon disease characteristics including sensitivity to retinoids and ATO and thereby underpins the need for rapid and accurate diagnosis and also demands a highly specific treatment approach. In this article we laid emphasis on the rearrangement of the RARα gene and its different fusion partners resulting in variant forms of APL, their implication in underlying molecular pathogenesis of APL and also the different diagnostic modalities that should be employed for their rapid and accurate diagnosis. Though patients are affected with APL worldwide, the incidence is highest among patients from Latin American descent.
Acute promyelocytic leukemia constitutes approximately 10% to 15% of acute myeloid leukemia (AML) cases, 3 affecting males and females equally. APL is considered as disease of the young with majority of cases diagnosed between 20 to 50 years of age. APL is rarely found in children less than 10 years old. However, number of studies have reported the incidence of t(15;17)(q22;q21) in neonates as well. 4 Though patients are affected with APL worldwide, the incidence is highest among patients from Latin American descent. [5] [6] [7] Although number of risk factors are associated with the development of APL, 8 accumulating evidence suggest that obesity has clinical implications in AML and APL in particular. [9] [10] [11] A higher BMI has been substantiated as risk factor for leukemia in particularly APL irrespective of gender or ethnicity. 10 Further, patients with APL with high BMI have a shorter survival 12, 13 and an increased risk of developing differentiation syndrome. 12 The fact that APL patients are more obese on an average than other forms of AML, obesity becomes an adverse prognostic factor for clinical outcome in APL patients.
Early detection of APL is of utmost importance in view of high risk of disseminated intravascular coagulation (DIC) especially in M3V APL patients. 14 
| DIAGNOSIS OF APL
Acute promyelocytic leukemia (APL) is a medical emergency requiring quick and precise diagnosis and an exceedingly specific treatment Cytogenetic testing should always be performed first in suspected APL patients. Although the results can be obtained in 48 to 72 hours, but the technique is labor intensive and only 80% to 85% of cases display the t(15;17) translocation due to poor quality metaphases, cryptic PML-RARα fusion, or presence of variant translocations. 15 FISH on metaphases and interphases has been shown to be a much rapid (24 hours) and more sensitive second line approach in detecting APL. The molecular approach (RT-PCR and Rq-PCR) provides rapid (6-8 hours) detection of the specific PML-RARα fusion transcript and help in monitoring minimal residual disease (MRD) at high sensitivity levels.
Flow cytometry is relatively fast and cost benefit with high sensitivity and has become a mandatory component in the initial workup of all newly diagnosed APL cases to establish cell lineage. It is clear that every technique has its own merit to aid in diagnosis of APL but molecular approach seems robust in both diagnosis and clinical management of the disease.
| CYTOLOGICAL AND CYTOCHEMICAL DIAGNOSIS
APL has 2 main morphologic variants, hypergranular or "typical" APL (M3) constituting about 60% to 70% and hypogranular or "microgranular" APL (M3V) that constitutes about 30% to 35% of APL cases as per the FAB classification. 16 In typical or M3 APL, the predominant cell is an abnormal promyelocyte, the cytoplasm of which is densely packed with coarse red or purple granules, which almost obscure the nucleus. 
| CYTOGENETIC EVALUATION
Cytogenetic analysis forms a mandatory routine diagnostic approach for any newly diagnosed and relapsed APL patient. Cytogenetics is a central prognostic determinant in this disease, predicting likelihood of successful remission induction, relapse risk and overall survival. 17 In 80% to 85% APL cases, presence of PML-RARα hybrid gene is predetermined by detection of t(15;17) 18 ( Figure 3 ). However, in approximately 15% APL patients with underlying PML-RARα rearrangements, this abnormality is not recognized. These include PML-RARα arising through insertion events, in which chromosomes 15 and 17 are forming PLZF-RARα gene is the most frequent APL variant. 20, 21 The t (5;17)(q35;q21) resulting in the rearrangement of NPM1 gene to RARα forming the NPM1-RARα fusion protein. 22 The other variants are very rare.
Certain cases have been reported which may represent new variants in themselves. These include t(14;17)(q22;q21), t(8;17)(p21;q21), t(1;17)(p36;q21), and t(7;17)(q36;q22). 23 Lately a case with t (12;15;17)(q24;q24;q11) resulting in PML-RARα hybrid gene on chromosome 12 has been reported. 24 Regardless of the disease complexity and rare failure of cytogenetic analysis in detecting t(15;17) in APL patients, still cytogenetic analysis should always be the first line of examinations to be carried out in patients presumed of having APL, since t(15;17) is ubiquitously present in most of these patients. samples (mean % age of positive cells+3 S.D.), which is about 10% with currently available probes.
| FLUORESCENT IN SITU HYBRIDIZATION

| REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-PCR)
RT-PCR has proved to be of great importance in molecular diagnosis of APL. Both bone marrow and peripheral blood can be used for analysis. 25 The technique is of great importance in APL diagnosis, provided false positives due to contamination and false negatives due to low quality of RNA, failures of RT or PCR steps, or use of inappropriate materials are avoided. 18 Furthermore, RT-PCR helps to determine PML breakpoint patterns which have prognostic significance. 26, 27 Diagnostic RT-PCR also helps in revealing reciprocal RARα-PML transcripts which are detectable in approximately 75% of patients. Mostly PLZF-RARα APL variant, express CD56 which is a poor prognostic indicator. 29 All variant forms of APL possess immunophenotypic features identical to classic APL.
| MINIMAL RESIDUAL DISEASE (MRD) MONITORING
Numerous pretreatment parameters are defined that help in prediction of an enhanced relapse risk in APL patients. 30 These include high total leukocyte count (TLC), low platelets, 31 CD56 status 32 along with FLT3 mutations 33 and pattern of PML breakpoints. These pretreatment characteristics currently lack the precision to guarantee optimal treatment intensity according to the requirements of individual cases.
This has engendered a prospect that MRD monitoring which has already been substantiated to provide independent prognostic information in APL, would fulfill its promise to allow precision in identification of cases which otherwise might relapse. 
37,38
There is a high likelihood of early death or relapse in patients that harbor the PML-RARαS transcript. 39 Numerous studies across the globe report consistent good clinical outcomes in all APL patients despite differential expression of various PML-RARα fusion transcripts due to highly effective nature of current therapy. 40 The reciprocal RARα-PML fusion gene generated in t ( and A regions. However, the sequences of B to F region are identical in both isoforms. Although the expression of RARα1 isoform is universal, expression of RARα2 isoform is more tissue specific and ATRA-dependent. 44 RARα display the conserved modular structure of nuclear receptors and its amino acid sequence can be fragmented into 6 regions (A-F) 45 ( Figure 4 ). 46 The 66 amino acid long central region C containing 2 zinc-binding motifs (zinc finger-like) forms the core of the DNA binding domain (DBD) that is necessary for the particular identification of kindred response elements (REs).
The 220 amino acid long region E is functionally complex because it seat the ligand binding domain (LBD), the ligand-dependent transcriptional activation function AF-2, and a dimerization surface.
Region D, which fall between the DBD and the LBD, has more conserved structure between the RAR types of a given species, but the D region of a given RAR particularly for the central part shows even greater interspecies conservation, 45, 47 thus indicating some as yet unknown function of this region of specific RAR type besides its hinge function. The function of carboxy-terminal regions F of the RAR types is unknown. In contrast, the amino-terminal A/B regions of RARs contain AF-1 which has second transcriptional activation function. 48 Each RAR type has various isoforms that result from alternative splicing. 45, 47 These isoforms differ in the nucleotide sequence of their A region. RARα and RARβ has 2 major isoforms each (αl and α2) and (βl and β2), whereas, RARγ has 4 major isoforms (γ1-γ4).
| THE MOLECULAR GENETICS OF APL-t(15;17)
t(15;17)(q22;q11-12), the underlying cause of APL is the balanced reciprocal translocation between chromosomes 17 and 15 that always involves the retinoic acid receptor (RARα) and PML gene (promyelocytic leukemia gene) in 95% to 98% of cases. 42, 49 The mechanism of this translocation is still unknown. It is hypothesized that cell clones containing the PML-RARα transcript that result from illegitimate recombinations during normal cell division survive elimination by DNA repair systems. 50 PML and RARα genes have strong tendency to rearrange as the 2 genes are found physically adjacent to one another in chromatin. 51 Upon fusion between PML and RARα, PML protein loses its variable C-terminus, whereas the constant N-terminal TRIM motif generally remains intact. On the contrary, RARα loses the first 50 to 60 N-terminal amino acids which does not affect either its DNA domain which mediates homo and hetero dimerization. 65 It is able to act as a transferable transcriptional repression domain 66 and also has 
TBLR1-RARα X-RARα (One Case) FIGURE 6 Translocations in acute promyelocytic leukemia with their respective frequencies a role in chromatin remodeling. 67 t(11;17)(q23;q21) resulting in PLZF-RARα fusion hosts the complete N-terminal transcription effector region of PLZF and the first 2 zinc fingers translocated to defined breakpoints of RARα. The reciprocal hybrid gene RARα-PLZF is present in nearly all the patients with t(11;17)(q23;q21).
21,68
These 2 fusion transcripts have antagonistic properties. It is known that PLZF-RARα suppresses gene transcription, while RARα-PLZF triggers it, 69 PLZF-RARα restrains cell growth, while RARα-PLZF enhances it by activating the expression of cyclin A2. 70 Hence ATRA resistant property of t(11;17)(q23;q21) might be attributed to the expression of these 2 reciprocal transcripts. It can be concluded that PLZF-RARα inhibits cell differentiation stimulated by ATRA, whereas
RARα-PLZF blocks the anti-proliferative effects of ATRA by activating cell cycle regulators.
Although the efficiency of arsenic tri-oxide (ATO) therapy is evident in APL as verified by the achievement of remission rate by >80% in relapsed/refractory patients but resistance to it still remains clinically critical problem in treatment. Compared to ATRA, information on ATO resistance remains limited but number of studies suggests that the PLZF-RARα hybrid gene is less sensitive to ATO than PML-RARα gene for a number of reasons.
APL patients expressing PLZF-RARα resist treatment to ATO as it primarily targets PML, which is absent in PLZF-RARα variant APL and therefore, shows a poor response. 71 Further ATO exclusively degrades PML-RARα, but not PLZF-RARα and thus variant confers resistance. 72 ATO resistance is substantiated by pattern immunostaining wherein the PML is rapidly changed by ATO, whereas the sub cellular localization of PLZF is not significantly affected. Also PLZF-RARα remains unaffected by SUMO-1 in the presence of ATO while as PML-RARα gets modified. 73 
| NUCLEOPHOSMIN GENE (NMP1) AND ITS FUSION WITH RARΑ-t(5;17)
The human NPM1 gene is situated on chromosome 5 and consists of 12 exons. Alternative splicing of this gene results in the formation of 2 isoforms which differ in their C-terminal region. 74, 75 In t(5;17) linked APL, RARα is translocated to nucleophosmin (NPM1) gene on chromosome 5q35. t(5;17) fuses the NPM1 gene to third exon of RARα forming 2 isoforms of the hybrid oncoprotein. 22 The t(5;17)(q35;q21) translocation was first elucidated in a 2-year-old female patient with APL. 76 This type of APL responds to both ATRA and chemotherapy.
Through interaction with co-repressor molecules, just like PML-RARα and PLZF-RARα, the NPM1-RARα transcript inhibits wild-type
RARα thus acting as its dominant negative inhibitor. 77 Also, NPM1-RARα could form homodimers, necessitating ATRA at pharmacological doses to let go the co-repressors.
A reciprocal RARα-NPM1 mRNA was detected in a patient with NPM1-RARα 22 and in another patient with t(5;17) APL. 19 However, the clinical importance of this reciprocal hybrid transcript is not known.
| NUCLEAR MITOTIC APPARATUS PROTEIN 1 GENE (NUMA1) & ITS FUSION WITH RARΑ-t(11;17)
NuMA1 gene is situated on chromosome 11q13 and encodes a 2115 amino acids protein that plays a significant role in completion of mitosis and reformation of nuclei in the post-mitotic daughter cells. 78, 79 The alternative splicing of the NuMA1 gene gives rise to 2 proteins of lengths 1776 and 1763 amino acids. 80 In 23 | t(7:17)(Q11;Q21)
Another form of APL with an unknown fusion partner of RARα has been reported. 90 The patient was a 70-year-old male presented with leukocytosis, thrombocytopenia and blasts in peripheral blood. The 
| CONCLUSION
Over the last more than 2 decades, the transformation of acute promyelocytic leukemia has been quite dramatic from the most aggressive subset of AML to a curable one. During these years, in addition the future however, is to find ways to bypass the blocking effect of PML-RARα on myeloid differentiation and this could change APL from being the most aggressive and lethal form of AML to the leukemia not requiring chemotherapy in large number of patients.
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